Mifepristone: Judge Orders US FDA To Rethink Need For REMS Restrictions

 
• By Sue Sutter
  
Homework
The FDA failed to "show its work" in justifying the 2023 REMS modifications.
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Litigation

More from United States